Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug-drug interaction (DDI) studies. The aim of this study was to build a whole-body physiologically based pharmacokinetic (PBPK) model...
Saved in:
Main Authors: | Fatima Zahra Marok (Author), Laura Maria Fuhr (Author), Nina Hanke (Author), Dominik Selzer (Author), Thorsten Lehr (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021) -
A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
by: Laura Maria Fuhr, et al.
Published: (2022) -
A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023) -
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024) -
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
by: Christina Kovar, et al.
Published: (2024)